Company-reported prevalence
SL1009
Overview
| Field | Value |
|---|---|
| Drug | SL1009 (sodium dichloroacetate) |
| Indication | Pyruvate dehydrogenase complex deficiency |
| Disease | Pyruvate dehydrogenase complex deficiency (PDCD) |
| Company | Saol Therapeutics (privately held; worldwide rights); Medosome Biotec collaborates on the companion dose-determining genetic test and holds no stated rights to the drug |
| Documents searched | Corporate website pages: SL1009 pipeline page (modified October 12, 2026), news index, About page, expanded access program policy (May 2025); press releases on saolrx.com and PR Newswire naming SL1009: February 13, 2023; March 16, 2023; February 12, 2024; December 3, 2024; January 28, 2025; April 17, 2025; June 19, 2025; September 8, 2025; December 9, 2025; July 7, 2026; July 28, 2026; September 15, 2026; no Form 10-K, 20-F, S-1, or annual report exists (privately held company); no corporate or investor presentation found |
| Data as of | October 14, 2026 |
| Prepared by | AI research agent (Claude); not yet reviewed by a person |
Company statements of prevalence
United States
Number affected: Saol Therapeutics press release, September 2025
Cited source: 2.1 Bedoyan 2024
(opens the full-size image in a new tab)Incidence: Saol Therapeutics press release, September 2025
Cited source: 2.1 Bedoyan 2024
(opens the full-size image in a new tab)Incidence: Saol Therapeutics website, October 2026
“Estimated US Incidence” (opens the source at this quote in a new tab)
“Approximately 90 Births per Year” (opens the source at this quote in a new tab)
Cited source: 2.2 Bedoyan 2020
(opens the full-size image in a new tab)Prevalence: Saol Therapeutics press release, January 2025
Cited source: None stated in the document.
(opens the full-size image in a new tab)Number treated: Saol Therapeutics press release, January 2025
Cited source: None stated in the document.
(opens the full-size image in a new tab)Number affected: Saol Therapeutics press release, February 2024
Cited source: None stated in the document.
(opens the full-size image in a new tab)Europe
No evidence found.
Global
No evidence found.
Other countries and regions
No evidence found.
Geography not stated
Number diagnosed: Saol Therapeutics website, October 2026
Cited source: 2.3 Ganetzky 2021; 2.4 National Organization for Rare Disorders 2021; 2.5 Genetic and Rare Diseases Information Center 2026
(opens the full-size image in a new tab)Sources the company cites
Bedoyan 2024
Passage carrying the nearest figure
(opens the full-size image in a new tab)Bedoyan 2020
Reference as the company lists it
(opens the full-size image in a new tab)
Ganetzky 2021
Reference as the company lists it
(opens the full-size image in a new tab)Passage carrying the figure
Not quoted: The chapter, read October 14, 2026, states no prevalence, incidence, frequency, or number of reported cases.
National organization for rare disorders 2021
Reference as the company lists it
(opens the full-size image in a new tab)Passage carrying the figure
(opens the full-size image in a new tab)Genetic and rare diseases information center 2026
Reference as the company lists it
(opens the full-size image in a new tab)Passage carrying the figure
Not quoted: The page, read October 14, 2026, states no prevalence, frequency, or number of reported cases for this disease.
References
- Bedoyan 2020 (opens in a new tab)
- Bedoyan 2024 (opens in a new tab)
- Ganetzky 2021 (opens in a new tab)
- Genetic and Rare Diseases Information Center (2026) (opens in a new tab)
- National Organization for Rare Disorders (2021) (opens in a new tab)
- Saol Therapeutics (2024) press release, February 12, 2024 (opens in a new tab)
- Saol Therapeutics (2025) press release, January 28, 2025 (opens in a new tab)
- Saol Therapeutics (2025) press release, September 8, 2025 (opens in a new tab)
- Saol Therapeutics (2026) website, pipeline page (opens in a new tab)